A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder

類似資料

• A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
  著者:: Gommoll, Carl P., 等
  出版事項: (2014)
• Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study
  著者:: Bakish, David, 等
  出版事項: (2014)
• Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
  著者:: Mago, Rajnish, 等
  出版事項: (2013)
• Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
  著者:: Mago, Rajnish, 等
  出版事項: (2013)
• Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials
  著者:: Montgomery, Stuart A., 等
  出版事項: (2014)